Ziconotide acetate (SNX-111 acetate), a peptide, is a potent and selective block of N-type calcium channels antagonist. Ziconotide acetate reduces synaptic transmission, and can be used for chronic pain research In Vitro Most native cells express a variety of different calcium channels and as a result, Ziconotide acetate only partially reduces high-voltage-activated calcium currents in differentiated human neuroblastoma IMR32 cells, rat superior cervical ganglion neurons, and rat hippocampal neurons. Ziconotide acetate also reduces calcium currents that result from expression of the α1B subunit in HEK cells, tsa-201 cells, and Xenopus laevis oocytes. Ziconotide acetate delivers its antinociceptive efficacy by reducing the release of pronociceptive neurotransmitters in the dorsal horn of the spinal cord, thereby inhibiting pain signal transmission. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo Ziconotide (i.t.; 25-100 pmol/site; 5 μL; on the 4 th, 10 th, 15 th, 20 th, and 24 th days) acetate reduces the levels of IL-1β and IL-23 in the CNS, as well as IL-17 production in the spleen, 25 days after MOG35-55-elicited EAE, in the mouse model of experimental autoimmune encephalomyelitis (EAE). MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Female C57BL/6mice (18-22 g, 6-8 weeks old) injected with myelin oligodendrocytes glycoproteinDosage: 25 pmol/site, 50 pmol/site, 100 pmol/site Administration: Intrathecal injection; on the 4 th, 10 th, 15 th, 20 th, and 24 th days Result: Significantly reduced the mechanical hypersensitivity in animals with EAE. Form:Solid IC50& Target:N-type calcium channel